Health-related quality of life for men with prostate cancer and diabetes: A longitudinal analysis from CaPSURE

被引:18
作者
Latini, David M.
Chan, June M.
Cowan, Janet E.
Arredondo, Shelley A.
Kane, Christopher J.
Penson, David F.
DuChane, Janeen
Carroll, Peter R.
机构
[1] Michael E DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Urol, Houston, TX 77030 USA
[3] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA
[4] Univ Calif San Francisco, Dept Urol, Program Urol Oncol, Genitourinary Canc Epidemiol & Populat Sci Progra, San Francisco, CA 94143 USA
[5] Univ Calif San Francisco, Ctr Comprehens Canc, Sch Med, San Francisco, CA 94143 USA
[6] Univ Calif San Francisco, Dept Epidemiol & Biostat, Sch Med, San Francisco, CA 94143 USA
[7] San Francisco VA Med Ctr, San Francisco, CA USA
[8] Univ So Calif, Dept Urol & Prevent Med, Keck Sch Med, Los Angeles, CA 90089 USA
[9] TAP Pharmaceut Prod Inc, Lake Forest, IL USA
关键词
D O I
10.1016/j.urology.2006.08.1096
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To compare diabetic versus nondiabetic men with prostate cancer to understand whether diabetes mellitus (DM) imposes an additional burden on health-related quality of life (HRQOL) before and after radical prostatectomy, adjusting for obesity. Methods. Data were abstracted from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a disease registry of 12,005 men with localized prostate cancer. Men were included who had undergone surgical treatment from 1989 to 2003, had body mass index (BMI) information available, and had completed both a pretreatment and at least one posttreatment HRQOL questionnaire within 24 months. A repeated-measures model adjusted for baseline clinical and demographic variables was used to evaluate group differences. Results. The 1248 men were divided into two groups (117 with DM and 1131 without DM) on the basis of a history of DM or the reporting of diabetes medication use. The diabetic men were significantly more likely to be older and nonwhite, have lower education and income, and be less likely to have private insurance. They also had significantly more comorbid conditions (other than DM) and a greater BM I at baseline. Urinary function differed by diabetes status, BMI, and the DM x BMI interaction, with diabetic men who had a greater BMI reporting greater declines in urinary function over time. No other statistically significant differences in HRQOL were observed, although trends by BMI were noted in sexual function and bowel bother. Conclusions. Although previous studies of men with prostate cancer have found differences in HRQOL by obesity level, our results have indicated that the presence or absence of DM and a high BMI may have a greater impact on HRQOL than obesity alone.
引用
收藏
页码:1242 / 1247
页数:6
相关论文
共 21 条
[1]  
Aiken L. S., 1991, Multiple regression: Testing and interpreting interactions
[2]   Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy [J].
Amling, CL ;
Riffenburgh, RH ;
Sun, L ;
Moul, JW ;
Lance, RS ;
Kusuda, L ;
Sexton, WJ ;
Soderdahl, DW ;
Donahue, TF ;
Foley, JP ;
Chung, AK ;
McLeod, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (03) :439-445
[3]   The impact of obesity on health related quality of life before and after radical prostatectomy (data from CaPSURE) [J].
Anast, JW ;
Sadetsky, N ;
Pasta, DJ ;
Bassett, WW ;
Latini, D ;
DuChane, J ;
Chan, JM ;
Cooperberg, MR ;
Carroll, PR ;
Kane, CJ .
JOURNAL OF UROLOGY, 2005, 173 (04) :1132-1138
[4]   Impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: Data from CaPSURE [J].
Arredondo, SA ;
Elkin, EP ;
Marr, PL ;
Latini, DM ;
DuChane, J ;
Litwin, MS ;
Carroll, PR .
UROLOGY, 2006, 67 (03) :559-565
[5]  
*CDCP, 2006, DIAB DIS DEADL RIS
[6]   The University of California, San Francisco cancer of the prostate risk assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy [J].
Cooperberg, MR ;
Pasta, DJ ;
Elkin, EP ;
Litwin, MS ;
Latini, DM ;
DuChane, J ;
Carroll, PR .
JOURNAL OF UROLOGY, 2005, 173 (06) :1938-1942
[7]   The contemporary management of prostate cancer in the United States: Lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a national disease registry [J].
Cooperberg, MR ;
Broering, JM ;
Litwin, MS ;
Lubeck, DP ;
Mehta, SS ;
Henning, JM ;
Carroll, PR .
JOURNAL OF UROLOGY, 2004, 171 (04) :1393-1401
[8]   Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Blank, K ;
Broderick, GA ;
Tomaszewski, JE ;
Renshaw, AA ;
Kaplan, I ;
Beard, CJ ;
Wein, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974
[9]   Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins [J].
Freedland, SJ ;
Terris, MK ;
Presti, JC ;
Amling, CL ;
Kane, CJ ;
Trock, B ;
Aronson, WJ .
JOURNAL OF UROLOGY, 2004, 172 (02) :520-524
[10]   Diabetes mellitus: A predictor for late radiation morbidity [J].
Herold, DM ;
Hanlon, AL ;
Hanks, GE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 43 (03) :475-479